RCKT (Rocket Pharmaceuticals) Net Cash per Share: $2.09 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RCKT Rocket Pharmaceuticals Inc RCKT
25 GF Score
Price $3.35
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals Net Cash per Share?

Rocket Pharmaceuticals RCKT -3.87% 25 Net Cash per Share is $2.09 as of Jun. 2026. GuruFocus rates RCKT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 775 Biotechnology companies, Rocket Pharmaceuticals ranks better than 87.1% on this metric.

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Rocket Pharmaceuticals's Net Cash per Share for the quarter that ended in Jun. 2026 was $2.09.

The historical rank and industry rank for Rocket Pharmaceuticals's Net Cash per Share or its related term are showing as below:

RCKT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.9   Med: 4.44   Max: 12.89
Current: 1.6

During the past 13 years, the highest Price-to-Net-Cash Ratio of Rocket Pharmaceuticals was 12.89. The lowest was 0.90. And the median was 4.44.

RCKT's Price-to-Net-Cash is ranked better than
87.1% of 775 companies
in the Biotechnology industry
Industry Median: 4.97 vs RCKT: 1.60

Rocket Pharmaceuticals  (NAS:RCKT) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Rocket Pharmaceuticals Net Cash per Share Related Terms


Rocket Pharmaceuticals Net Cash per Share Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals Net Cash per Share Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.37 3.72 3.32 2.89 1.25

Rocket Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 1.56 1.25 0.89 2.09

RCKT vs BNTC, AVIR, LRMR: Net Cash per Share Comparison

For the Biotechnology subindustry, Rocket Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals Price-to-Net-Cash vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Price-to-Net-Cash falls into.


RCKT
25GF Score
Rocket Pharmaceuticals Inc RCKT
Net Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Rocket Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as

Net Cash per Share (A: Dec. 2025 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(188.929-53.228-0)/108.320
=1.25

Rocket Pharmaceuticals's Net Cash per Share for the quarter that ended in Jun. 2026 is calculated as

Net Cash per Share (Q: Jun. 2026 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(283.747-54.268-0)/109.539
=2.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Cash per Share →
What does a Net Cash per Share of $2.09 mean?
Rocket Pharmaceuticals (RCKT) has a Net Cash per Share of $2.09 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Rocket Pharmaceuticals and its competitors. According to the industry distribution chart, Rocket Pharmaceuticals ranks #100 out of 775 companies in the Biotechnology industry, placing it in the top 12.9%.
Is Rocket Pharmaceuticals' Net Cash per Share too high?
Rocket Pharmaceuticals' current Net Cash per Share is $2.09. The Biotechnology industry median Net Cash per Share is 4.97. Rocket Pharmaceuticals' value of $2.09 is 57.9% below this industry median. Based on the distribution chart, Rocket Pharmaceuticals ranks #100 out of 775 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rocket Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' Net Cash per Share compare to BNTC and AVIR?
According to the Biotechnology industry distribution chart, Rocket Pharmaceuticals ranks #100 out of 775 companies for Net Cash per Share. This places Rocket Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 4.97. Rocket Pharmaceuticals' value of $2.09 is 57.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.97, based on 775 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rocket Pharmaceuticals's current Net Cash per Share of $2.09 is 57.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Rocket Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rocket Pharmaceuticals's current Net Cash per Share is $2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current Net Cash per Share of $2.09. The current Net Cash per Share is $2.09 and 57.9% below the Biotechnology industry median of 4.97. Rocket Pharmaceuticals' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current Net Cash per Share is $2.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
25GF Score

Get the complete analysis for RCKT

Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.35
Price